District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05646316
Recruiting
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Stage I Uterine Corpus Cancer AJCC v8
Register for Updates
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459
Recruiting
This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program... Read More
Gender:
Male
Ages:
16 years and above
Trial Updated:
05/03/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Hemophilia B
Register for Updates
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766
Recruiting
Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Georgetown University Medical Centre, Washington, District of Columbia
Conditions: Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia
Register for Updates
Nasotracheal Intubation With VL vs DL in Infants Trial
NCT05433155
Recruiting
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal int... Read More
Gender:
All
Ages:
Between 1 day and 365 days
Trial Updated:
05/03/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Intubation Complication, Intubation; Difficult or Failed, Hypoxia, Hypoxemia, Anesthesia Intubation Complication, Pediatric HD
Register for Updates
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
Recruiting
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: MedStar Georgetown University Hospital ( Site 4005), Washington, District of Columbia
Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Register for Updates
A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
NCT05064878
Recruiting
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
Gender:
All
Ages:
Between 1 year and 35 years
Trial Updated:
05/03/2024
Locations: Ep0216 149, Washington, District of Columbia
Conditions: CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Register for Updates
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
NCT03340675
Recruiting
Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respir... Read More
Gender:
Male
Ages:
7 years and above
Trial Updated:
05/03/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Register for Updates
Protocol CAUSE-03 / CHEETAH
NCT06136091
Recruiting
This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the partici... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/02/2024
Locations: Children's National Medical Center: Children's Research Institute, Washington, District of Columbia
Conditions: Asthma
Register for Updates
Treatment of Hypopigmented Scars With Bimatoprost
NCT06122090
Recruiting
Patients who have hypo-pigmented burn scar will have two scars chosen and randomized to treated scar and control scar. The subject will then have both scars treated with fractional ablative CO2 laser (FLSR). The treated scar will have bimatoprost delivered through the laser channels, while the control will have the vehicle (normal saline) only delivered. The treatment will continue for 14 days with twice daily application. The scars will then be monitored at a 2-week follow-up visit where levels... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen [PSA] after surgical removal of the pros... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
NCT04453293
Recruiting
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG will be compared with a placebo (an inactive vaccine). BCG (Japan) is used globally but is not approved for use in the United States, therefore it is considered experimental. Participants choosing to take part in this research study, will be randomly assigned... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: MedStar Washington Hospital Center/MedStar Health Research Institute, Washington, District of Columbia
Conditions: Tuberculosis Infection
Register for Updates